Journal of Antimicrobial Chemotherapy (2002) 49, 21-30
© 2002 The British Society for Antimicrobial Chemotherapy
Supplement |
AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Avenue, Pomona, CA 91768, USA
Abstract
Amphotericin B is the treatment of choice for life-threatening systemic fungal infections such as candidosis and aspergillosis. To improve this drug's efficacy and reduce its acute and chronic toxicities, several lipid formulations of the drug have been developed, including AmBisome, a liposomal formulation of amphotericin B. The liposome is composed of high transition temperature phospholipids and cholesterol, designed to incorporate amphotericin B securely into the liposomal bilayer. AmBisome can bind to fungal cell walls, where the liposome is disrupted. The amphotericin B, after being released from the liposomes, is thought to transfer through the cell wall and bind to ergosterol in the fungal cell membrane. This mechanism of action of AmBisome results in its potent in vitro fungicidal activity while the integrity of the liposome is maintained in the presence of mammalian cells, for which it has minimal toxicity. In animal models, AmBisome is effective in treating both intracellular (leishmaniasis and histoplasmosis) and extracellular (candidosis and aspergillosis) systemic infections. Because of its low toxicity at the organ level, intravenous AmBisome can be safely delivered at markedly high doses of amphotericin B (1–30 mg/kg) for the treatment of systemic fungal infections. AmBisome has a circulating half-life of 5–24 h in animals, and in animal models appears to localize at sites of infection in the brain (cryptococcosis, aspergillosis, coccidioidomycosis), lungs (blastomycosis, paracoccidioidomycosis, aspergillosis) and kidneys (candidosis), delivering amphotericin B that remains bioavailable in tissues for several weeks following treatment.
Notes
* Corresponding author. Tel/Fax: 1-626-794-8766; E-mail: jpadler{at}csupomona.edu
Present address. 11 N. Altura Road, Arcadia, CA 91007, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. A. Cornely, J. Maertens, M. Bresnik, A. J. Ullmann, R. Ebrahimi, and R. Herbrecht Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B J. Antimicrob. Chemother., November 3, 2009; (2009) dkp397v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. Amato, F. F. Tuon, A. M. Siqueira, A. C. Nicodemo, and V. A. Neto Treatment of Mucosal Leishmaniasis in Latin America: Systematic Review Am J Trop Med Hyg, August 1, 2007; 77(2): 266 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takemoto, Y. Yamamoto, Y. Ueda, Y. Sumita, K. Yoshida, and Y. Niki Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis J. Antimicrob. Chemother., April 1, 2006; 57(4): 724 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Charvalos, M. N. Tzatzarakis, F. Van Bambeke, P. M. Tulkens, A. M. Tsatsakis, G. N. Tzanakakis, and M.-P. Mingeot-Leclercq Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects J. Antimicrob. Chemother., February 1, 2006; 57(2): 236 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Xiong, S. A. Hassan, W. K. Wilson, X. Y. Han, G. S. May, J. J. Tarrand, and S. P. T. Matsuda Cholesterol Import by Aspergillus fumigatus and Its Influence on Antifungal Potency of Sterol Biosynthesis Inhibitors Antimicrob. Agents Chemother., February 1, 2005; 49(2): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bellocchio, R. Gaziano, S. Bozza, G. Rossi, C. Montagnoli, K. Perruccio, M. Calvitti, L. Pitzurra, and L. Romani Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4 J. Antimicrob. Chemother., February 1, 2005; 55(2): 214 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gaziano, S. Bozza, S. Bellocchio, K. Perruccio, C. Montagnoli, L. Pitzurra, G. Salvatori, R. De Santis, P. Carminati, A. Mantovani, et al. Anti-Aspergillus fumigatus Efficacy of Pentraxin 3 Alone and in Combination with Antifungals Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4414 - 4421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Falk, J. Grunwald, A. Hoffman, A. J. Domb, and I. Polacheck Distribution of Amphotericin B-Arabinogalactan Conjugate in Mouse Tissue and Its Therapeutic Efficacy against Murine Aspergillosis Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3606 - 3609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Tempone, D. Perez, S. Rath, A. L. Vilarinho, R. A. Mortara, and H. F. de Andrade Jr Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine J. Antimicrob. Chemother., July 1, 2004; 54(1): 60 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Clemons and D. A. Stevens Comparative Efficacies of Four Amphotericin B Formulations--Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet--against Systemic Murine Aspergillosis Antimicrob. Agents Chemother., March 1, 2004; 48(3): 1047 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Ibrahim, V. Avanessian, B. Spellberg, and J. E. Edwards Jr. Liposomal Amphotericin B, and Not Amphotericin B Deoxycholate, Improves Survival of Diabetic Mice Infected with Rhizopus oryzae Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3343 - 3344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Espuelas, P. Legrand, M. A. Campanero, M. Appel, M. Cheron, C. Gamazo, G. Barratt, and J. M. Irache Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice J. Antimicrob. Chemother., September 1, 2003; 52(3): 419 - 427. [Abstract] [Full Text] [PDF]
|
|